[Comment] Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance

The immune microenvironment is now recognised as crucial in the treatment of cancer. The tumour immune infiltrate has been noted to be associated with better outcomes in HER2-positive breast cancer and triple-negative breast cancer (TNBC), in both the early-stage and the advanced disease setting.1,2 Incorporating the quantity of the pre-existing immune response with other prognostic clinical pathological factors, such as tumour size and nodal status, will allow clinicians to better estimate long-term survival after breast cancer diagnosis.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research